In vivo studies with chimeric toxins. Interleukin-2 fusion toxins as immunosuppressive agents.
Shapiro
M E
ME
Beth Israel Hospital, Boston, Massachusetts.
Kirkman
R L
RL
Kelley
V R
VR
Bacha
P
P
Nichols
J C
JC
Strom
T B
TB
D000818:Animals; D001327:Autoimmune Diseases / Q000628:therapy; D004167:Diphtheria Toxin / Q000627:therapeutic use*; D005098:Exotoxins / Q000627:therapeutic use*; D006084:Graft Rejection / Q000187:drug effects; D006968:Hypersensitivity, Delayed / Q000628:therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000922:Immunotoxins / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use*; D051379:Mice; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D011994:Recombinant Proteins
C054780:DAB(486)-interleukin 2; D004167:Diphtheria Toxin; D005098:Exotoxins; C057961:IL-2-PE40 chimeric protein, recombinant; D007166:Immunosuppressive Agents; D000922:Immunotoxins; D007376:Interleukin-2; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins